NIH-funded research R01 grant

Time-limited trials to guide care for seriously ill patients in the ICU

Official title: A Type 2 Hybrid Effectiveness-Implementation Study of Time Limited Trials to Reduce Potentially Non-Beneficial Treatments for Critically Ill Patients with Advanced Medical Illnesses

Funded at Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · NIH-11423659 · Data updated 2026-11-12

A real-world study tests using structured, time-limited conversations and agreed-upon treatment plans to help seriously ill patients and their families avoid non-beneficial ICU care.

More Critically Ill research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
NIH-funded
Lab location1 site (Torrance, United States)
Project startSeptember 25, 2025
Project endAugust 31, 2030
Funding year2026
Award (this year)$654,728
NIH project number5R01AG095167-02
Project IDNIH-11423659 on NIH RePORTER

Who could benefit from this research

Could help

Adults with advanced medical illnesses admitted to ICUs who and their surrogates are willing to engage in time-limited trial discussions.

Less likely to help

Patients unlikely to participate in structured discussions or who have goals incompatible with the time-limited trial approach.

What this research studies

This project tests a structured approach where clinicians, patients, and surrogate decision-makers discuss goals of care and prognosis, agree on specific time-limited treatment plans, and reassess at defined intervals. It uses a pragmatic stepped-wedge design in ICU settings to see if the approach can be scaled in real healthcare systems. The goal is to improve shared decision-making, ensure care aligns with patient goals, and reduce use of treatments that may not help and could prolong suffering.

Why it matters

Potential benefit: If successful, patients may receive care that better matches their goals and avoid unwanted aggressive treatments.

How similar studies have gone: Preliminary data from a pilot suggested improved decision-making and reduced non-beneficial ICU treatments with TLTs.

Where this research is happening

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
    Torrance, United States
    Active

Researchers

  • Principal investigator: Chang, Dong Wook — Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
  • Study coordinator: Chang, Dong Wook

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.